BioSpace News Archive

DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced that Vitality Group has chosen the company’s digital therapeutics solutions for inclusion in Vitality’s new Gateway Flex offering.

Epirium Bio, Inc., a clinical-stage biopharmaceutical company pursuing novel and clinically significant therapeutic approaches for neuromuscular, neurodegenerative and mitochondrial disorders, today announced the appointment of Alexander Casdin as chief financial officer (CFO) and member of the company’s executive team.

ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA ) , a pioneer of Thermo Acoustic Enhanced UltraSound, has been issued international registration certificates (patents) DM/210628 and DM/210629 by the World Intellectual Property Organization (WIPO).

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will present new analyses from a Phase 2b clinical trial with nebulized ensifentrine in chronic obstructive pulmonary disease at CHEST Annual Meeting 2020 taking place on October 18-21.

In its Seventh Year, the Global Campaign Highlights Importance of a Condition that Contributes to One in Four Deaths Worldwide and Poses a High Risk for COVID-19 Patients

Further growth of leadership team with hire of highly experienced drug developer

MorphoSys AGtoday announces to launch an offering of unsubordinated, unsecured convertible bonds due 2025 in an aggregate principal amount of approximately EUR 325 million.

Dynacure acquires intellectual property from Paris Brain Institute to support DYN201 development

Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, announced that it has dosed the first patients in its Phase 2 clinical trial evaluating EDP1815 for the treatment of mild to moderate psoriasis.

POINT Biopharma Inc., a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, announces its CEO, Dr. Joe McCann, will present at the 2020 BIO Investor Forum.